UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
Commission File Number:
(State or other jurisdiction of |
(I.R.S. Employer | |
incorporation or organization) | Identification No.) | |
|
| |
(Address of principal executive offices) |
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. Entry into a Material Definitive Agreement.
On May 11, 2023, AmerisourceBergen Corporation (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase 292,792 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), directly from the Selling Stockholder (the “Repurchase”). The Repurchase was consummated on May 15, 2023. The aggregate price paid by the Company in the Repurchase was approximately $50 million. The Repurchase was made under the Company’s share repurchase program and the repurchased shares will be held in treasury.
The foregoing description of the Share Repurchase Agreement is qualified in its entirety by reference to the full text of the Share Repurchase Agreement filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 8.01. Other Events.
The Repurchase was carried out concurrently with the Selling Stockholder entering into variable pre-paid forward sale contracts (the “Contracts”) with financial institutions, executed in reliance on Rule 144 of the Securities Act of 1933, as amended. The Contracts are scheduled to settle starting in the fourth quarter of the Selling Stockholder’s fiscal year 2025, at which time the Selling Stockholder intends to deliver 4,590,000 shares of Common Stock in the aggregate to the counterparties to the Contracts. In exchange for assuming these obligations, the Selling Stockholder received cash payments from the financial institutions in an aggregate amount of approximately $644 million.
After giving effect to the impact of the Repurchase, the Selling Stockholder owns 33,366,388 shares of Common Stock, which represents approximately 16.5% of the 202,173,212 total outstanding shares of Common Stock of the Company (based on 202,466,004 shares of Common Stock outstanding as of April 30, 2023, less the 292,792 shares of Common Stock repurchased in the Repurchase).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
Description | ||
10.1 | Share Repurchase Agreement, dated as of May 11, 2023, by and between AmerisourceBergen Corporation and Walgreens Boots Alliance Holdings LLC. | ||
104 | Cover Page Interactive Data File (formatted as inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AmerisourceBergen Corporation | ||
May 15, 2023 | By: | /s/ James F. Cleary |
Name: James F. Cleary | ||
Title: Executive Vice President and Chief Financial Officer |